Q1 2024 EPS Estimates for Pfizer Inc. (NYSE:PFE) Lifted by Zacks Research

Posted by on Jun 24th, 2023

Pfizer Inc. (NYSE:PFE – Get Rating) – Equities research analysts at Zacks Research increased their Q1 2024 earnings estimates for Pfizer in a research note issued on Thursday, June 22nd. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings per share of $0.99 for the quarter, up from their previous estimate of $0.98. The consensus estimate for Pfizer’s current full-year earnings is $3.35 per share.

PFE has been the subject of several other research reports. JPMorgan Chase & Co. set a $45.00 price objective on Pfizer in a research report on Monday, February 27th. Wells Fargo & Company cut their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. UBS Group decreased their target price on shares of Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Morgan Stanley dropped their price target on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. Finally, Daiwa Capital Markets lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price objective for the company. in a research report on Thursday, May 11th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $47.33.

Pfizer Trading Down 1.1 %

PFE opened at $38.30 on Friday. The stock has a market cap of $216.22 billion, a PE ratio of 7.54, a PEG ratio of 1.33 and a beta of 0.64. The business has a 50 day moving average of $38.71 and a 200-day moving average of $42.73. Pfizer has a 52 week low of $36.17 and a 52 week high of $54.93. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31.

Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The company had revenue of $18.28 billion for the quarter, compared to analysts’ expectations of $16.49 billion. During the same quarter last year, the company earned $1.62 EPS. The firm’s revenue was down 28.8% compared to the same quarter last year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be issued a dividend of $0.41 per share. The ex-dividend date is Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.28%. Pfizer’s payout ratio is 32.28%.

Insider Buying and Selling

In related news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Friday, May 5th. The stock was acquired at an average cost of $38.42 per share, for a total transaction of $38,420.00. Following the purchase, the director now owns 5,000 shares in the company, valued at $192,100. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Lam Group Inc. bought a new position in Pfizer in the fourth quarter worth approximately $25,000. 25 LLC bought a new position in Pfizer in the 1st quarter worth $25,000. Worth Asset Management LLC purchased a new position in Pfizer during the first quarter valued at $29,000. My Personal CFO LLC bought a new stake in Pfizer during the fourth quarter valued at about $32,000. Finally, Mendota Financial Group LLC purchased a new stake in Pfizer in the fourth quarter worth about $33,000. 67.80% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.